Extremely premature infants born at 23-25 weeks gestation are at substantial risk for pulmonary hypertension
© 2022. The Author(s)..
OBJECTIVE: Extremely low gestational age newborns (ELGANs) represent an especially vulnerable population. Herein, we aimed to determine incidence and severity of pulmonary hypertension associated with bronchopulmonary dysplasia (BPD-PH) in extremely immature ELGANs (gestational age: 230/6-256/7 weeks).
METHODS: In this prospective observational cohort study, we assessed BPD-PH by means of several echocardiography markers and serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels at 3 and 12 months of chronological age. In addition, we analyzed incidence and efficacy of pharmacologic treatment for BPD-PH.
RESULTS: At 3 months 15/34 ELGANs had echocardiographic evidence of BPD-PH, while at 12 months of age 6/34 still had PH. PH-targeted therapy consisted of sildenafil monotherapy in 11 and dual oral combination therapy (sildenafil and macitentan) in four ELGANs at 3 and 12 months.
CONCLUSION: 44% (15/34) of ELGANs developed BPD-PH. All received PH-targeted pharmacotherapy at 3 months, leading to hemodynamic improvements at 12 months in most infants.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Journal of perinatology : official journal of the California Perinatal Association - 42(2022), 6 vom: 01. Juni, Seite 781-787 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sallmon, Hannes [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BW9B0ZE037 |
|---|
| Anmerkungen: |
Date Completed 13.06.2022 Date Revised 17.11.2022 published: Print-Electronic CommentIn: J Pediatr. 2022 Nov;250:110-112. - PMID 35944715 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41372-022-01374-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338956735 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338956735 | ||
| 003 | DE-627 | ||
| 005 | 20231226001831.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41372-022-01374-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1129.xml |
| 035 | |a (DE-627)NLM338956735 | ||
| 035 | |a (NLM)35365772 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sallmon, Hannes |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Extremely premature infants born at 23-25 weeks gestation are at substantial risk for pulmonary hypertension |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.06.2022 | ||
| 500 | |a Date Revised 17.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Pediatr. 2022 Nov;250:110-112. - PMID 35944715 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a OBJECTIVE: Extremely low gestational age newborns (ELGANs) represent an especially vulnerable population. Herein, we aimed to determine incidence and severity of pulmonary hypertension associated with bronchopulmonary dysplasia (BPD-PH) in extremely immature ELGANs (gestational age: 230/6-256/7 weeks) | ||
| 520 | |a METHODS: In this prospective observational cohort study, we assessed BPD-PH by means of several echocardiography markers and serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels at 3 and 12 months of chronological age. In addition, we analyzed incidence and efficacy of pharmacologic treatment for BPD-PH | ||
| 520 | |a RESULTS: At 3 months 15/34 ELGANs had echocardiographic evidence of BPD-PH, while at 12 months of age 6/34 still had PH. PH-targeted therapy consisted of sildenafil monotherapy in 11 and dual oral combination therapy (sildenafil and macitentan) in four ELGANs at 3 and 12 months | ||
| 520 | |a CONCLUSION: 44% (15/34) of ELGANs developed BPD-PH. All received PH-targeted pharmacotherapy at 3 months, leading to hemodynamic improvements at 12 months in most infants | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Sildenafil Citrate |2 NLM | |
| 650 | 7 | |a BW9B0ZE037 |2 NLM | |
| 700 | 1 | |a Koestenberger, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Avian, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Reiterer, Friedrich |e verfasserin |4 aut | |
| 700 | 1 | |a Schwaberger, Bernhard |e verfasserin |4 aut | |
| 700 | 1 | |a Meinel, Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Cvirn, Gerhard |e verfasserin |4 aut | |
| 700 | 1 | |a Kurath-Koller, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Gamillscheg, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Hansmann, Georg |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of perinatology : official journal of the California Perinatal Association |d 1993 |g 42(2022), 6 vom: 01. Juni, Seite 781-787 |w (DE-627)NLM01262943X |x 1476-5543 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:6 |g day:01 |g month:06 |g pages:781-787 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41372-022-01374-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2022 |e 6 |b 01 |c 06 |h 781-787 | ||